STAT+: Kymera reports early-stage success for drug meant to rival Sanofi and Regeneron’s Dupixent

Kymera Therapeutics reported that an experimental drug designed to rival Sanofi and Regeneron’s blockbuster therapy Dupixent succeeded in a closely watched early-stage trial.